diclofenac and am 251
diclofenac has been researched along with am 251 in 3 studies
Research
Studies (3)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Fujimoto, S; Kunimatsu, M; Mori, M; Tsushima, H | 1 |
| Chambers, MG; Jassal, K; Johnson, MP; McDougall, JJ; Oskins, JL; Schuelert, N | 1 |
| Nawata, Y; Yamaguchi, T; Yamamoto, T | 1 |
Other Studies
3 other study(ies) available for diclofenac and am 251
| Article | Year |
|---|---|
Capsaicin-induced, capsazepine-insensitive relaxation of the guinea-pig ileum.
Topics: 4-Aminopyridine; Acetylcholine; Animals; Apamin; Barium; Benzopyrans; Caffeine; Calcitonin Gene-Related Peptide; Calcium; Capsaicin; Charybdotoxin; Diclofenac; Dimethyl Sulfoxide; Diterpenes; Dose-Response Relationship, Drug; Enzyme Inhibitors; Glyburide; Guanethidine; Guinea Pigs; Ileum; In Vitro Techniques; Intracellular Signaling Peptides and Proteins; Male; Muscle Relaxation; Muscle, Smooth; Myosin Light Chains; Nitroarginine; Papaverine; Peptide Fragments; Phosphodiesterase Inhibitors; Phosphorylation; Piperidines; Potassium Channel Blockers; Potassium Channels; Potassium Chloride; Protein Serine-Threonine Kinases; Pyrazoles; Receptor, Cannabinoid, CB1; rho-Associated Kinases; Tetraethylammonium; Vasodilator Agents | 2006 |
Local application of the endocannabinoid hydrolysis inhibitor URB597 reduces nociception in spontaneous and chemically induced models of osteoarthritis.
Topics: Action Potentials; Afferent Pathways; Age Factors; Animals; Arthralgia; Benzamides; Carbamates; Diclofenac; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Guinea Pigs; Indoles; Iodoacetic Acid; Male; Nociceptors; Osteoarthritis; Piperidines; Pyrazoles; Rats; Rats, Wistar; Time Factors; Weight-Bearing | 2011 |
[JSNP Excellent Presentation Award for AsCNP 2011: improvement of cognitive impairments on withdrawal after repeated methamphetamine by administration of a cannabinoid CB1 receptor antagonist and a COX inhibitor].
Topics: Animals; Awards and Prizes; Cognition Disorders; Cyclooxygenase Inhibitors; Diclofenac; Male; Methamphetamine; Mice; Mice, Inbred ICR; Mice, Knockout; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Substance Withdrawal Syndrome | 2012 |